tiprankstipranks
Silence Therapeutics (DE:XRP2)
FRANKFURT:XRP2
Holding DE:XRP2?
Track your performance easily

Silence Therapeutics (XRP2) Income Statement

6 Followers

Silence Therapeutics Income Statement

Last quarter (Q4 2022), Silence Therapeutics's total revenue was £4.76M, an increase of 39.57% from the same quarter last year. In Q4, Silence Therapeutics's net income was £-13.76M. See Silence Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
£ 17.50M£ 25.38M£ 17.50M£ 12.41M£ 5.48M£ 244.00K
Cost of Revenue
£ 10.88M£ 10.32M£ 10.88M£ 7.46M£ 3.76M-
Gross Profit
£ 6.62M£ 15.06M£ 6.62M£ 4.96M£ 1.72M£ 244.00K
Operating Expense
£ 55.21M£ 64.66M£ 55.21M£ 50.77M£ 34.19M£ 22.98M
Operating Income
£ -48.59M£ -49.60M£ -48.59M£ -45.81M£ -32.48M£ -22.73M
Net Non Operating Interest Income Expense
£ 179.00K£ 1.41M£ 179.00K£ -2.00K£ -113.00K£ 6.00K
Other Income Expense
---£ -44.00K£ -3.68M-
Pretax Income
£ -47.37M£ -50.31M£ -47.37M£ -45.86M£ -36.04M£ -22.87M
Tax Provision
£ -6.88M£ -7.04M£ -6.88M£ -6.45M£ -3.49M£ -3.29M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
£ -40.49M£ -43.27M£ -40.49M£ -39.41M£ -32.55M£ -19.58M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
£ 66.09M£ 74.98M£ 66.09M£ -58.23M£ -37.95M£ -22.98M
Net Income From Continuing And Discontinued Operation
£ -40.49M£ -43.27M£ -40.49M£ -39.41M£ -32.55M£ -19.58M
Normalized Income
£ -40.49M£ -57.35M£ -54.25M£ -52.30M£ -39.53M£ -26.16M
Interest Expense
£ 47.00K-----
EBIT
£ -47.32M£ -50.28M£ -47.32M£ -45.85M£ -36.02M£ -22.84M
EBITDA
£ -46.84M£ -49.78M£ -46.84M-£ -35.53M£ -22.36M
Currency in GBP

Silence Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis